Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET
Company Participants
Nichol Ochsner - Vice President of Investor Relations
Neil McFarlane - President and Chief Executive Officer
Christal Mickle - Co-Founder and Chief Product Development Officer
LaDuane Clifton - Chief Financial Officer, Secretary and Treasurer
Joshua Schafer - Chief Commercial Officer and Executive Vice President, Business Development
Conference Call Participants
Louise Chen - Cantor Fitzgerald
Jonathan Aschoff - ROTH MKM
Sumant Kulkarni - Canaccord
Oren Livnat - H.C. Wainwright
Operator
Good morning, everyone. Thank you for joining the Zevra Therapeutics Third Quarter 2023 Corporate Updates and Financial Results Call. Today's call is being recorded and will be made available on the company's website following the conclusion of the call.
With that, I will now turn the call over to Nichol Ochsner, Vice President of Investor Relations and Corporate Communications for Zevra Therapeutics. Please go ahead.
Nichol Ochsner
Good morning and thank you for joining us today to review Zevra Therapeutics progress in the third quarter of 2023, outlining our clinical advances, operational achievements and financial results.
Before we get started, let me take a moment to provide some important information. First, I encourage you to access the press release, which was published this morning and is available in the Investors section of the Zevra website. While we will not be using slides on today's call, an updated corporate presentation will be made available on our website later today.
As we move forward, it's important to highlight that the company's discussions will include forward-looking statements. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties and other significant factors that may lead to actual results differing materially from the projections made. For a comprehensive understanding of these factors, please refer to the Risk Factors section in our most recent quarterly report on Form 10-Q and our annual report on Form 10-K.
I am pleased to welcome Zevra's management team members participating in today's call. I'm joined by Neil McFarlane, President and Chief Executive Officer; LaDuane Clifton, our Chief Financial Officer; Joshua Schafer, our Chief Commercial Officer and EVP of Business Development; and Christal Mickle, our Chief Development Officer.
With that, I'll turn the call over to Neil.
Neil McFarlane
Thank you, Nichol, and thank you all for making the time to join us today. It's truly an honor for me to have the opportunity to lead Zevra at this critical stage of our growth and to build on the company's solid foundation as we work towards achieving multiple near-term clinical and regulatory milestones along with accelerating our rare disease commercial capabilities to bring therapies to patients.